Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
38.54 USD | +0.10% | +13.25% | +90.37% |
05-09 | Oppenheimer Adjusts Tarsus Pharmaceuticals Price Target to $61 From $59, Maintains Outperform Rating | MT |
05-08 | Transcript : Tarsus Pharmaceuticals, Inc., Q1 2024 Earnings Call, May 08, 2024 |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+90.37% | 1.45B | |
+33.09% | 709B | |
+30.84% | 595B | |
-2.35% | 367B | |
+20.29% | 334B | |
+4.76% | 289B | |
+14.13% | 239B | |
+9.19% | 211B | |
-3.35% | 203B | |
+8.54% | 171B |
- Stock Market
- Equities
- TARS Stock
- News Tarsus Pharmaceuticals, Inc.
- Oppenheimer Raises Tarsus Pharmaceuticals Price Target to $59 From $55, Maintains Outperform Rating